Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
840 stopped studies mapped to Malignant Prostate Neoplasm and descendants · 92% state a reason
Over the 840 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT05807126 | Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP… | Phase 1 | withdrawn | Apr 11, 2023 | National Cancer Institute (NCI) | No subjects enrolled in the study | Enrollment / accrual |
| NCT04927559 | Health Literacy in Understanding Radiation Therapy Information in Patients Undergoing… | — | terminated | Jun 16, 2021 | University of Southern California | Low accrual | Enrollment / accrual |
| NCT04458311 | Abiraterone Acetate in Combination With Tildrakizumab(ACTIon) | Phase 1 / Phase 2 | terminated | Jul 7, 2020 | Institute of Cancer Research, United Kingdom | Funder decided that response outcomes to date did not support continuation of the study. | Other (stated, no rule matched) |
| NCT04633148 | Dose-escalating Trial With UniCAR02-T Cells and PSMA Target Module (TMpPSMA) in Patients… | Phase 1 | terminated | Nov 18, 2020 | AvenCell Europe GmbH | Although IMP has been well tolerated, biological activity was very limited. The sponsor concluded… | Other (stated, no rule matched) |
| NCT01393119 | Phase II, Dose Finding Study of GTx-758 | Phase 2 | terminated | Jul 13, 2011 | GTx | FDA Clinical Hold | Other (stated, no rule matched) |
| NCT04677855 | Study of PCUR-101 in Combination With ADT in Patients With mCRPC | Phase 1 | terminated | Dec 21, 2020 | Pellficure Pharmaceuticals, Inc | Business Decision due to insufficient enrollment | Enrollment / accrual |
| NCT03810105 | A Study of Olaparib and Durvalumab in Prostate Cancer | Phase 2 | terminated | Jan 18, 2019 | Memorial Sloan Kettering Cancer Center | Due to low accrual | Enrollment / accrual |
| NCT06355843 | Clinical Applications of Integrated PET/MR and PET/CT in the Diagnosis and Treatment of… | N/A | suspended | Apr 9, 2024 | The First Affiliated Hospital of Anhui Medical University | The 68Ge/68Ga generator is currently at the end of its lifespan. We are trying to purchase new… | Other (stated, no rule matched) |
| NCT05445882 | N-803 Alone or in Combination With BN-Brachyury Vaccine or Bintrafusp Alfa (M7824) for… | Phase 2 | withdrawn | Jul 6, 2022 | National Cancer Institute (NCI) | Closed by study team, no subjects enrolled. | Enrollment / accrual |
| NCT04243941 | PSMA-PET/MRI Low- and Intermediate-Risk Prostate Cancer | Phase 2 | withdrawn | Jan 28, 2020 | UNC Lineberger Comprehensive Cancer Center | Funding unavailable | Funding |
| NCT04586335 | Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With… | Phase 1 | terminated | Oct 14, 2020 | Haihe Biopharma Co., Ltd. | Business decision | Sponsor / business decision |
| NCT03657108 | CivaSheet With Radical Prostatectomy & Adjuvant External Beam Radiation | N/A | terminated | Sep 4, 2018 | Icahn School of Medicine at Mount Sinai | Decision made by DSMB to terminate study in April 2023. | Other (stated, no rule matched) |
| NCT03909893 | A Study of Adaptive Radiation Therapy for Pelvic Genitourinary Cancer(ARTGU) | N/A | withdrawn | Apr 10, 2019 | University Health Network, Toronto | This study is being closed. The protocol may be reviewed and consolidated under a new study… | Other (stated, no rule matched) |
| NCT05361915 | Study to Assess Abivertinib in Combination With Abiraterone in Metastatic Castration… | Phase 2 | suspended | May 5, 2022 | Sorrento Therapeutics, Inc. | Sorrento Therapeutics filed for chapter 11 bankruptcy. | Other (stated, no rule matched) |
| NCT05574712 | A Neoadjuvant Study of Abiraterone Acetate, Leuprolide Acetate, and Belzutifan in Men… | Phase 2 | withdrawn | Oct 10, 2022 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Principal Investigator has decided not to activate this trial. | Investigator |
| NCT02933801 | ODM-201 Maintenance Therapy in Patients With mCRPC Previously Treated With Novel Hormonal… | Phase 2 | terminated | Oct 14, 2016 | Swiss Cancer Institute | Decision Board no further financial support after 3 years of follow-up as remaining patients in… | Funding |
| NCT03533946 | Rucaparib in Nonmetastatic prOstAte With BRCAness(ROAR) | Phase 2 | terminated | May 23, 2018 | University of Utah | New standard of care for study participant population | Other (stated, no rule matched) |
| NCT05034562 | Gallium-68 PSMA-11 PET in Participants With Prostate Cancer | Phase 2 | withdrawn | Sep 5, 2021 | M.D. Anderson Cancer Center | Per PI no participants enrolled | Enrollment / accrual |
| NCT00019695 | Ketoconazole With or Without Alendronate Sodium in Treating Patients With Metastatic… | Phase 2 | terminated | Mar 5, 2007 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT03878524 | Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME… | Phase 1 | terminated | Mar 18, 2019 | OHSU Knight Cancer Institute | Low accrual | Enrollment / accrual |
| NCT05156372 | Adjuvant High-intensity Interval Training During Chemotherapy in Metastatic Prostate…(HIIT PCa) | N/A | withdrawn | Dec 14, 2021 | The University of Texas Health Science Center at San Antonio | PI left the institution, no subjects were enrolled | Investigator |
| NCT05169372 | Retrospective Analysis of 68Ga-PSMA-PET in Patients With Prostate Cancer: Experience From…(PET-PSMA) | — | terminated | Dec 23, 2021 | Latin American Cooperative Oncology Group | LACOG and Astellas decided to end the study due to the great difficulty in finding patients with… | Other (stated, no rule matched) |
| NCT04727736 | 18F-DCFPyL Positron Emission Tomography (PET) in Intermediate or High Risk Prostate Cancer | Phase 2 | terminated | Jan 27, 2021 | Ashok Muthukrishnan | Intervention became FDA-approved | Other (stated, no rule matched) |
| NCT02279693 | Evaluation of the Dose Received by the Prostate With in Vivo Dosimetry in Patients…(PROSTRACK) | N/A | terminated | Oct 31, 2014 | Centre Georges Francois Leclerc | feasibility problem | Other (stated, no rule matched) |
| NCT03577028 | Study of HPN424 in Patients With Advanced Prostate Cancer | Phase 1 / Phase 2 | terminated | Jul 5, 2018 | Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Decision not to continue to the expansion portion of the study | Other (stated, no rule matched) |
| NCT02995330 | Sex-Mismatched Allogeneic Bone Marrow Transplantation for Men With Metastatic… | Phase 1 | terminated | Dec 16, 2016 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | lack of accrual | Enrollment / accrual |
| NCT03970863 | Focal Therapy for Localized Prostate Cancer | — | withdrawn | Jun 3, 2019 | China Medical University Hospital | difficulty in recruiting participants | Enrollment / accrual |
| NCT04844749 | Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One…(VERACITY) | Phase 3 | terminated | Apr 14, 2021 | Veru Inc. | Administrative reasons | Other (stated, no rule matched) |
| NCT04264208 | HDR Brachytherapy 68-Ga-RM2 PET, 68-Ga-PSMA-11 PET &Multi Parametric MRI in Prostate… | Phase 2 | terminated | Feb 11, 2020 | Andrei Iagaru | Lack of accrual due to pandemic and logistics | COVID-19 / pandemic |
| NCT05673109 | A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer | Phase 1 | terminated | Jan 6, 2023 | Accutar Biotechnology Inc | Subject benefit-risk ratio changes, sponsor decides to voluntarily terminate study | Other (stated, no rule matched) |
| NCT04304079 | A Novel Augmented Reality System (ARssist) for the Assistant Surgeon in Robotic Assisted… | N/A | withdrawn | Mar 11, 2020 | Chinese University of Hong Kong | No funding | Funding |
| NCT05238831 | SMMART Adaptive Clinical Treatment (ACT) Trial | Early Phase 1 | withdrawn | Feb 14, 2022 | OHSU Knight Cancer Institute | Withdrawn due to a change in therapeutic interventions. | Other (stated, no rule matched) |
| NCT05035732 | A Prospective Pilot Study for the Evaluation of 18F- Fluciclovine PET/MRI in… | N/A | withdrawn | Sep 5, 2021 | M.D. Anderson Cancer Center | 0 participant accrual | Enrollment / accrual |
| NCT05124795 | IMU-935 in Patients With Progressive, Metastatic Castration Resistant Prostate Cancer | Phase 1 | terminated | Nov 18, 2021 | Immunic AG | Lack of Efficacy | Efficacy / futility |
| NCT04528199 | [18F]FLOR (FC303) PET/CT Imaging in Patients With Prostate Cancer | Phase 1 | terminated | Aug 27, 2020 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | The Principal Investigator decided to terminate the study because the PI left Hopkins. | Investigator |
| NCT00323180 | Investigation of Protein Biomarkers of Prostate Cancer | — | withdrawn | May 9, 2006 | University of New Mexico | PI left institution and no subjects enrolled and this is not a clinical trial. | Investigator |
| NCT00323388 | Identification of Risk Allels for Prostate Cancer | — | withdrawn | May 9, 2006 | University of New Mexico | No subjects enrolled and this is not a clinical trial. Was inadvertently entered in the system. | Enrollment / accrual |
| NCT04409288 | Patient Preference of Apalutamide Versus Enzalutamide in Patients With Recurrent or… | Phase 3 | terminated | Jun 1, 2020 | Chinese University of Hong Kong | Endpoint reached | Other (stated, no rule matched) |
| NCT00176631 | Licorice Root Extract and Docetaxel in Treating Patients With Metastatic Prostate Cancer… | Phase 2 | terminated | Sep 15, 2005 | Rutgers, The State University of New Jersey | slow accrual | Enrollment / accrual |
| NCT00633087 | A Phase I/II Trial of 2-Deoxyglucose (2DG) for the Treatment of Advanced Cancer and…(2-Deoxyglucose) | Phase 1 / Phase 2 | terminated | Mar 11, 2008 | Rutgers, The State University of New Jersey | Slow accrual | Enrollment / accrual |
| NCT03494803 | Detection of Prostate Cancer With Non-invasive Method Based on DNA Methylation of… | — | withdrawn | Apr 11, 2018 | HKGepitherapeutics | No participants enrolled, leading to insufficient patient numbers to initiate the clinical trial. | Enrollment / accrual |
| NCT03837353 | A Parallel Arm Phase 1b/2a Study of DKN-01 as Monotherapy or in Combination With… | Phase 1 / Phase 2 | terminated | Feb 12, 2019 | NYU Langone Health | Terminated early due to slow accrual in the context of changing practice patterns. | Enrollment / accrual |
| NCT03338712 | Micro-RNA Expression Profiles in Localised Prostate Cancer | — | withdrawn | Nov 9, 2017 | Wuerzburg University Hospital | Principal Investigators no longer in business | Sponsor / business decision |
| NCT05425862 | Pidnarulex and Talazoparib in Patients With Metastatic Castration Resistant Prostate…(REPAIR) | Phase 1 | suspended | Jun 21, 2022 | Peter MacCallum Cancer Centre, Australia | Enrolment suspended to further assess supplementary non-clinical study data. | Enrollment / accrual |
| NCT06159998 | New Markers for Treatment Response to Radiotherapy in Prostate Cancer | — | withdrawn | Dec 7, 2023 | University of Basel | Study closed | Other (stated, no rule matched) |
| NCT03861403 | A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus… | Phase 1 | terminated | Mar 4, 2019 | Leap Therapeutics, Inc. | Product development discontinued unrelated to safety. | Safety / toxicity |
| NCT03550040 | 3D Versus Robot Assisted Laparoscopic Prostatectomy. | N/A | terminated | Jun 8, 2018 | Tampere University Hospital | accrual was sufficient at interim analysis to draw final conclusions needed to publish | Efficacy / futility |
| NCT05910697 | Clinical Utility of MyProstateScore 2.0 P2 | N/A | terminated | Jun 20, 2023 | Qure Healthcare, LLC | The decision to stop the study was made by the sponsor, based solely on timeline constraints. | Other (stated, no rule matched) |
| NCT05454371 | Investigation of Urinary Biomarkers for the Detection of Prostate Cancer(URODETECT-WP2) | N/A | withdrawn | Jul 12, 2022 | Novosanis NV | Study is part of PhD trajectory and currently the trajectory is in the final phases without the… | Enrollment / accrual |
| NCT05405439 | To Evaluate the Efficacy of TQB3823 Combined With Abiraterone and Prednisone in… | Phase 1 / Phase 2 | terminated | Jun 6, 2022 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | The sponsor voluntarily terminated the study | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated May 2, 2024source: clinicaltrials